Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARMP Armata Pharmaceuticals	$2.67 +4.7%	$0.00	$1.07 ▼ $5.26	$96.34M	0.85	17,560 shs	9,559 shs
PAA Plains All American Pipeline	$17.94 +1.4%	$16.99	$12.07 ▼ $19.03	$12.58B	1.59	3.41 million shs	3.39 million shs
TRX TRX Gold	$0.47 +2.2%	$0.38	$0.31 ▼ $0.60	$131.09M	0.65	350,151 shs	435,720 shs

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARMP Armata Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
PAA Plains All American Pipeline	+1.90%	-1.61%	+3.03%	+13.25%	+35.14%
TRX TRX Gold	+3.27%	+0.46%	+23.12%	+27.38%	-14.05%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARMP Armata Pharmaceuticals	2.0928 of 5 stars	3.5	3.0	0.0	1.9	1.7	0.6
PAA Plains All American Pipeline	1.7287 of 5 stars	2.3	0.0	1.7	2.5	0.8	1.9
TRX TRX Gold	3.2762 of 5 stars	3.5	0.0	0.0	3.1	0.0	3.1

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARMP Armata Pharmaceuticals	3.00	Buy	$7.00	162.66% Upside
PAA Plains All American Pipeline	2.55	Moderate Buy	$18.96	5.68% Upside
TRX TRX Gold	3.00	Buy	$1.58	235.11% Upside

Current Analyst Ratings

Latest ARMP, PAA, RNO, TRX, and EX1 Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2024	PAA Plains All American Pipeline	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $22.00
4/16/2024	TRX TRX Gold	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1.50 ➝ $1.75
4/16/2024	TRX TRX Gold	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1.30 ➝ $1.40
4/12/2024	PAA Plains All American Pipeline	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $22.00
4/12/2024	PAA Plains All American Pipeline	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$14.50 ➝ $16.00
4/8/2024	PAA Plains All American Pipeline	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$23.00
3/22/2024	ARMP Armata Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
3/19/2024	PAA Plains All American Pipeline	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $23.00
3/1/2024	PAA Plains All American Pipeline	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$16.50 ➝ $17.50

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARMP Armata Pharmaceuticals	$4.53M	21.27	N/A	N/A	($0.89) per share	-2.99
PAA Plains All American Pipeline	$48.71B	0.26	$3.38 per share	5.30	$16.31 per share	1.10
TRX TRX Gold	$38.01M	3.45	$0.01 per share	34.23	$0.23 per share	2.04

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARMP Armata Pharmaceuticals	-$69.04M	-$1.98	N/A	N/A	N/A	-1,524.51%	-280.95%	-52.61%	5/9/2024 (Estimated)
PAA Plains All American Pipeline	$1.23B	$1.39	12.91	14.02	N/A	2.39%	10.48%	4.33%	5/3/2024 (Confirmed)
TRX TRX Gold	$2.25M	$0.01	47.05	5.88	N/A	0.70%	-1.66%	-1.18%	N/A

Latest ARMP, PAA, RNO, TRX, and EX1 Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/3/2024	N/A	PAA Plains All American Pipeline	$0.37	N/A	-$0.37	N/A	N/A	N/A
4/12/2024	Q2 2024	TRX TRX Gold	N/A	$0.01	+$0.01	N/A	$9.40 million	$7.98 million
3/21/2024	Q4 2023	ARMP Armata Pharmaceuticals	N/A	-$0.55	-$0.55	-$0.55	$0.68 million	$1.53 million
2/9/2024	12/31/2023	PAA Plains All American Pipeline	$0.36	$0.42	+$0.06	$0.49	$14.30 billion	$12.70 billion

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARMP Armata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PAA Plains All American Pipeline	$1.27	7.08%	-15.92%	91.37%	3 Years
TRX TRX Gold	N/A	N/A	N/A	N/A	N/A

Latest ARMP, PAA, RNO, TRX, and EX1 Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/4/2024	PAA Plains All American Pipeline	quarterly	$0.3175	6.7%	4/30/2024	5/1/2024	5/15/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARMP Armata Pharmaceuticals	N/A	1.16	1.16
PAA Plains All American Pipeline	0.64	0.98	0.87
TRX TRX Gold	N/A	0.93	0.61

Ownership

Institutional Ownership

Company	Institutional Ownership
ARMP Armata Pharmaceuticals	3.57%
PAA Plains All American Pipeline	41.78%
TRX TRX Gold	1.06%

Insider Ownership

Company	Insider Ownership
ARMP Armata Pharmaceuticals	85.50%
PAA Plains All American Pipeline	0.75%
TRX TRX Gold	2.25%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ARMP Armata Pharmaceuticals	66	36.15 million	5.24 million	Not Optionable
PAA Plains All American Pipeline	4,200	701.07 million	695.81 million	Optionable
TRX TRX Gold	130	278.92 million	272.64 million	Optionable

ARMP, PAA, RNO, TRX, and EX1 Headlines

Source	Headline
	Equities Analysts Offer Predictions for TRX Gold Co.'s FY2024 Earnings (NYSE:TRX) marketbeat.com - April 19 at 8:50 AM
	Roth Capital Equities Analysts Lift Earnings Estimates for TRX Gold Co. (NYSE:TRX) americanbankingnews.com - April 19 at 3:02 AM
	Roth Capital Weighs in on TRX Gold Co.'s FY2025 Earnings (NYSE:TRX) marketbeat.com - April 18 at 6:48 AM
	Is TRX Gold Corporation's (TSE:TRX) Recent Stock Performance Influenced By Its Fundamentals In Any Way? finance.yahoo.com - April 17 at 7:27 PM
	Roth MKM Keeps Their Buy Rating on Tanzanian Royalty Exploration (TRX) markets.businessinsider.com - April 17 at 2:27 PM
	TRX Gold (NYSE:TRX) Price Target Increased to $1.75 by Analysts at Alliance Global Partners americanbankingnews.com - April 17 at 4:36 AM
	TRX Gold (NYSE:TRX) Price Target Increased to $1.40 by Analysts at HC Wainwright americanbankingnews.com - April 17 at 3:48 AM
	TRX Gold (NYSE:TRX) Receives New Coverage from Analysts at StockNews.com americanbankingnews.com - April 17 at 2:14 AM
	Buy Rating Affirmed for Tanzanian Royalty Exploration Amid Strong Financials and Operational Advancements markets.businessinsider.com - April 16 at 2:03 PM
	TRX Gold (NYSE:TRX) PT Raised to $1.75 at Alliance Global Partners marketbeat.com - April 16 at 1:28 PM
	TRX Gold nears completion of plant expansion at Buckreef gold project proactiveinvestors.com - April 15 at 8:42 AM
	TRX Gold Corporation: TRX Gold Expects Significant Growth with Plant Expansion Nearing Completion finanznachrichten.de - April 15 at 7:59 AM
	TRX Gold (NYSE:TRX) Issues Earnings Results americanbankingnews.com - April 15 at 7:08 AM
	TRX Gold Expects Significant Growth with Plant Expansion Nearing Completion globenewswire.com - April 15 at 6:30 AM
	Crypto Whale Incoming: Tron (TRX) And Litecoin (LTC) Exceed Expectations, Whilst Scorpion Casino (SCORP) Nears Its Official Launch outlookindia.com - April 13 at 7:45 AM
	TRX Stock Earnings: TRX Gold Misses Revenue for Q2 2024 markets.businessinsider.com - April 12 at 11:24 PM
	BlockDAG Presale Triumph: Eyeing $10 Value With 20,000x ROI Amidst TRON’s Decline And Upcoming Bitcoin Halving finbold.com - April 12 at 8:21 AM
	TRON Sees Whale Outflows; Bonk Aims For New ATH; NuggetRush Becomes Retail Favorite finbold.com - April 10 at 8:42 AM
	TRX Gold (NYSE:TRX) Coverage Initiated at StockNews.com americanbankingnews.com - April 9 at 2:20 AM
	NuggetRush’s Presale Sparks Interest Over WIF and TRON Predictable Plays msn.com - April 7 at 1:09 PM
	TRX Gold Reports 2023 Annual Meeting Voting Results globenewswire.com - April 5 at 4:05 PM
	Technology and transition in agriculture ocj.com - April 4 at 6:14 PM
	New things to do in Kuala Lumpur in 2024 thesmartlocal.com - April 4 at 9:21 AM
	Step into the most expensive and luxurious cinemas around the globe msn.com - April 3 at 12:10 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Armata Pharmaceuticals

NYSEAMERICAN:ARMP

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

Plains All American Pipeline

NYSE:PAA

Plains All American Pipeline, L.P., through its subsidiaries, engages in the pipeline transportation, terminaling, storage, and gathering of crude oil and natural gas liquids (NGL) in the United States and Canada. The company operates through two segments, Crude Oil and NGL. The Crude Oil segment offers gathering and transporting crude oil through pipelines, gathering systems, trucks, and on barges or railcars. This segment provides terminaling, storage, and other facilities-related services, as well as merchant activities. The NGL segment is involved in natural gas processing and NGL fractionation, storage, transportation, and terminaling. This segment also includes ethane, propane, normal butane, iso-butane, and natural gasoline derived from natural gas production and processing activities, as well as crude oil refining processes. Its NGL components are used for various applications, such as heating, engine, and industrial fuels. The company was founded in 1981 and is headquartered in Houston, Texas. Plains All American Pipeline, L.P. operates as a subsidiary of Plains GP Holdings, L.P.

TRX Gold

NYSE:TRX

TRX Gold Corporation engages in the exploration, development, and production of mineral property interests in the United Republic of Tanzania. The company primarily explores for gold deposits. It holds interests in the Buckreef gold project that comprises a single Special Mining License covering an area of 16.04 square kilometers and 12 Prospecting Licenses covering 98.19 square kilometers located in north-central Tanzania. The company was formerly known as Tanzanian Gold Corporation and changed its name to TRX Gold Corporation in May 2022. TRX Gold Corporation was incorporated in 1990 and is based in Oakville, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial